Assessing the need for pioglitazone in the treatment of patients with type 2 diabetes: a meta-analysis of its risks and benefits from prospective trials
Crossref DOI link: https://doi.org/10.1038/s41598-020-72967-8
Published Online: 2020-09-25
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Sinha, Binayak
Ghosal, Samit
Text and Data Mining valid from 2020-09-25
Version of Record valid from 2020-09-25
Article History
Received: 5 August 2019
Accepted: 8 September 2020
First Online: 25 September 2020
Competing interests
: The authors declare no competing interests.